00:42 , Jun 22, 2019 |  BioCentury  |  Product Development

Is tau the new amyloid?

After finally getting the message that they need to look beyond amyloid to treat Alzheimer’s disease, pharmas are lining up behind tau as the next big target. The question is whether they can pick out...
20:16 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

AADvac1: Ph I data

A double-blind, placebo-controlled, Austrian Phase I trial in 30 patients ages 50-85 with mild to moderate AD showed that once-monthly subcutaneous AADvac1 for 3 months led to an IgG immune response in 29 patients. The...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

AADvac1: Phase II started

Axon Neuroscience began the double-blind, placebo-controlled, European Phase II ADAMANT trial to evaluate subcutaneous AADvac1 given monthly for 6 months followed by 2 booster doses given in 6-month intervals in about 185 patients. Axon Neuroscience...